XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
BUSINESS DESCRIPTION (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended
Apr. 02, 2021
Jun. 26, 2020
Sep. 07, 2018
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Apr. 30, 2020
Apr. 13, 2020
Business Acquisition [Line Items]                  
Oncology test reporting time       1 day          
Net loss         $ 6,300,000        
Working deficiency         11,400,000        
Net cash used in operating activities         (5,177,000) $ (5,983,000)      
Issuance of common stock in connection with at the market offering, net of issuance costs         14,947,000        
Proceeds from issuance of common stock         $ 16,207,000 6,921,000      
Proceeds from PPP Loan           $ 787,000      
Common stock, par value         $ 0.01   $ 0.01    
Sale of common stock           2,060,000      
Term of test reporting time for patients         1 day        
Maximum                  
Business Acquisition [Line Items]                  
Oncology test reporting time       10 days          
Term of test reporting time for patients         10 days        
Minimum                  
Business Acquisition [Line Items]                  
Oncology test reporting time       7 days          
Term of test reporting time for patients         7 days        
Sales Agreement with Alliance Global Partners                  
Business Acquisition [Line Items]                  
Proceeds from issuance of common stock $ 15,400,000                
Maximum aggregate initial offering price                 $ 50,000,000.0
Common stock, par value $ 0.01                
Sale of common stock 4,501,000                
Additional shares available for future sales $ 6,600,000                
Sales Agreement with Alliance Global Partners | Maximum                  
Business Acquisition [Line Items]                  
Proceeds from issuance of common stock $ 22,000,000.0                
Lincoln Park [Member]                  
Business Acquisition [Line Items]                  
Issuance of common stock in connection with at the market offering, net of issuance costs     $ 10,000,000            
Shares sold in offering (in shares)       0   1,040,654      
Proceeds from issuance of common stock       $ 0   $ 1,400,000      
Sale of common stock   4,500,000              
Joint Venture [Member]                  
Business Acquisition [Line Items]                  
Percentage of interest in joint venture               49.00%  
Joint Venture [Member] | Poplar Put Right [Member] | Scenario, Plan [Member]                  
Business Acquisition [Line Items]                  
Percentage of interest in joint venture               100.00%  
Price per share               $ 1.00  
Purchase price               $ 51  
Joint Venture [Member] | Popular Healthcare PLLC [Member]                  
Business Acquisition [Line Items]                  
Percentage of interest in joint venture               51.00%